Drug regulator halts obeticholic acid production, orders recall

The DCGI has sought the cancellation of manufacturing licences for obeticholic acid (5mg and 10mg tablets), used to treat primary biliary cholangitis (PBC), following similar actions by the US FDA and the European Medicines Agency.
Read the full story on Mint Opens livemint.com in a new tab
This is a short summary of a story published by Mint, shown with a link to the original. The full story, photo and reporting belong to Mint.











